CDK4/6 inhibitor plus endocrine therapy for hormone receptor‐positive, HER2‐negative metastatic breast cancer: The new standard of care

Author:

Hui Rina12,Boer Richard34,Lim Elgene56,Yeo Belinda78,Lynch Jodi9

Affiliation:

1. Crown Princess Mary Cancer Centre Westmead Hospital Sydney New South Wales Australia

2. University of Sydney Sydney New South Wales Australia

3. Peter MacCallum Cancer Centre Melbourne Victoria Australia

4. Epworth‐Freemasons Private Hospital Melbourne Victoria Australia

5. St. Vincent's Clinical School University of New South Wales Sydney New South Wales Australia

6. Garvan Institute of Medical Research Sydney New South Wales Australia

7. Austin Health Melbourne Victoria Australia

8. Olivia Newton‐John Cancer Research Institute Melbourne Victoria Australia

9. Cancer Care Centre St George Public Hospital Kogarah New South Wales Australia

Publisher

Wiley

Subject

Oncology,General Medicine

Reference72 articles.

1. CDK4/6 inhibitors in breast cancer: current controversies and future directions;Spring LM;Curr Oncol Rep,2019

2. CDK4/6 inhibitors: game changers in the management of hormone receptor‐positive advanced breast cancer?;Shah M;Oncology (Williston Park),2018

3. Targeted therapy for premenopausal women with HR+, HER2– advanced breast cancer: focus on special considerations and latest advances;Bardia A;Clin Cancer Res,2018

4. CDK4/6 inhibition in breast cancer: current practice and future directions;Pernas S;Ther Adv Med Oncol,2018

5. Are all cyclin‐dependent kinases 4/6 inhibitors created equal?;Marra A;npj Breast Cancer,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3